Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

CytomX Therapeutics, Inc. CTMX

Healthcare  —  Biotechnology
2.70 (0.05) (1.82%) as of 25 Sep
Market cap
$599.2M
P/E
0.0×
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K
Quarterly (Descending) Quarterly (Ascending) Annual (Descending) Annual (Ascending) TTM (Descending) TTM (Ascending)
Download Excel — free account
Older periods Sep '25 Dec '25 Mar '26 Jun '26
P/E ratio

+8 more quarters

 8.00 0.00 0.00 0.00
P/S ratio 4.63 7.71 23.44 44.86
P/FCF ratio 0.00 0.00 0.00 0.00
P/Operating CF (33.85) (25.28) (32.61) (45.44)
P/B ratio 4.90 5.93 2.60 2.72
Price to Tangible BV 4.97 6.02 2.62 2.73
EV/Sales 3.41 5.97 13.82 27.01
EV/EBITDA 17.41 0.00 0.00 0.00
EV/Operating CF (5.36) (6.02) (6.13) (6.00)
EV/FCF (5.35) (6.00) (6.11) (5.98)
Quick Ratio 3.54 2.98 10.21 9.25
Current Ratio 3.64 3.09 10.38 9.36
Net Debt/EBITDA 8.83 4.87 17.21 13.16
Debt/Assets 0.00% 0.00% 0.00% 0.00%
Debt/Equity 0.00 0.00 0.00 0.00
Asset Turnover 0.76 0.56 0.16 0.07
Operating CF/Net income 1.09 0.79 1.40 0.87
Capex/Depreciation (0.25) 0.96 0.00 0.00
Interest Coverage 0.00 0.00 0.00 0.00
Research and Development Expense of Revenue 256.65% 3,202.71% 187.54% 1,241.04%
Selling, General and Administrative Expense of Revenue 107.78% 1,110.11% 104.23% 536.04%
Intangible Assets out of Total Assets 0.01 0.01 0.00 0.00
Share Based Compensation of Revenue 23.21% 223.08% 45.88% 181.73%
Graham Net Nets 0.19 0.16 0.38 0.36
Graham Number 2.42 0.00 0.00 0.00
Earnings Yield 12.50% (0.97%) (8.75%) (13.33%)
Free Cash Flow Yield (13.75%) (12.90%) (9.64%) (10.06%)
Revenue per Share 0.04 0.00 0.06 0.01
Operating CF per Share (0.09) (0.17) (0.14) (0.08)
Capex per Share 0.00 0.00 0.00 0.00
Free Cash Flow per Share (0.09) (0.17) (0.14) (0.08)
Cash per Share 0.87 0.99 1.96 1.51
Shareholders Equity per Share 0.65 0.72 1.80 1.38
Interest Debt per Share 0.00 0.00 0.00 0.00
Book value per Share 0.65 0.72 1.80 1.38
Free Cash Flow (15.42) (23.44) (25.55) (18.07)
Working Capital 108.19 97.31 319.07 333.29
Capital Expenditures 0.13 (0.20) — —
Net Current Asset Value 98.35 91.36 313.68 294.00
EV/EBIT 16.66 0.00 0.00 0.00
Capex to Sales (0.02) 0.30 0.00 0.00
Net Profit Margin (238.62%) (4,451.28%) (177.89%) (1,457.40%)
Price to Operating Income 22.64 0.00 0.00 0.00
Other line items
Average Receivables 2.49 2.56 1.30 19.68
Average Payables 1.03 1.19 0.82 1.08
Average Assets 148.62 136.05 228.93 278.14
Average Common Equity 41.97 49.28 172.50 210.99

Fold the line items

Columns are period end dates